Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – April 1, 2026 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chr...
Disclosure of the total number of voting rights and shares composing the share capital as at March 31, 2026 Disclosure of the total number of voting rights and shares composing the share capital as at March 31, 2026 Articles L. 233-8-II of the French Commercial Code and 223-16 of the General Regulation of the Autorité des Marchés Financiers Saint-Rémy-lès-Chevreuse, April 1, 2026 DateTotal number of sharesTheoretical total number of voting rights1Net total number of voting rights2March 31, 202637,117,77237,117,77237,064,515 Investor Relations Contact / 64 ...
Information relative au nombre total de droits de vote et d'actions composant le capital social au 31 mars 2026 Information relative au nombre total de droits de vote et d’actions composant le capital social au 31 mars 2026 Articles L. 233-8-II du Code de commerce et 223-16 du Règlement général de l’Autorité des marchés financiers Saint-Rémy-lès-Chevreuse, le 1er avril 2026 DateNombre total d’actions composant le capitalNombre total de droits de vote théoriques1Nombre total de droits de vote nets231 mars 202637 117 77237 117 77237 064 515 Contact Relations Investisseurs : / 64 ...
A director at ID Logistics bought 1,500 shares at 309.709EUR and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Abivax Announces Full Year 2025 Financial Results and Provides Business Updates Abivax Announces Full Year 2025 Financial Results and Provides Business Updates ABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on March 18, 2026 found no new safety signals; the analysis included 100% of patients randomized, with nearly 90% having completed the 44-week double blind maintenance trialThe Company’s pivotal Phase 3 ABTECT maintenance trial evaluating obefazimod for moderately to severely active ulcerative colitis remains on track to report topline results in late Q2 2026Abivax appointed...
In 2025, OPmobility (OPM) once again demonstrated its ability to weather a challenging market environment, driven by an attractive product and geographic positioning, as well as consistently exemplary cost discipline. In this study, we analyze the levers available to the equipment manufacturer to navigate an industry that remains as unpredictable as ever in 2026, thereby preserving its BB+ rating.
OPmobility (OPM) a de nouveau démontré en 2025 sa capacité à absorber un environnement de volumes défavorable, portée par un positionnement produit et géographique séduisant, ainsi que par une discipline de coûts toujours exemplaire. Dans cette étude, nous analysons les leviers dont dispose l’équipementier pour naviguer au sein d’une industrie toujours aussi imprévisible en 2026, et ainsi préserver sa notation BB+.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.